A Mixed Methods Study of Chronic Kidney Disease (CKD) Self-Management

项目总结 2019年末，新冠肺炎，一种由严重急性呼吸综合征冠状病毒2引起的疾病- 冠状病毒(CoV-2)出现在武汉，中国，并迅速影响了几乎世界所有国家。官方 新冠肺炎被世界卫生组织宣布为全球大流行，是一种世界性紧急事件， 与直接、当前的体外模型平台相结合的数百万人与人类感染是如此不同，以至于它们可能无法捕捉病毒感染或病毒与宿主相互作用的关键成分。 2020年5月29日，全球报告了超过5.8例新冠肺炎病例，超过36万人死亡。虽然起源于中国，但美国已成为这一大流行的震中，报告的新冠肺炎病例超过175万例 超过10.3万人死亡。不幸的是，目前还没有可以预防SARS-CoV-2感染或强效的疫苗 活跃的抗病毒药物，可以减轻感染或改变疾病进展。更有甚者 鉴于这一地方性、全国性和全球性的紧急情况，我们的近期目标是发展新的和强大的 实验细胞培养模型，病毒学工具，并确定治疗SARS-CoV-2的新疗法。 我们的长期目标是阐明SARS-CoV-2感染的复杂相互作用和机制 和主人的反应。鉴于我们的机构一直处于美国新冠肺炎疫情的中心， 我们已经生成了一个广泛的临床数据数据库，显示出初始COVID的高流行率- 19例患者有胃肠道症状，超过一半的患者有生化证据。 出现肝脏损伤的可能性。SARS-CoV-2感染对肝细胞和胆管细胞的影响 功能仍不清楚。为了解决这些知识差距，我们产生了几项新技术 并组建了一支强大的团队，拥有干细胞生物学、组织工程和 病毒学、化学筛查和干细胞生物学，以及病毒学/BSL3专业知识。我们的目标是识别毒品 影响SARS-CoV-2病毒感染的候选病毒，同时我们评估主机与病毒的相互作用。 鉴于SARS-CoV-2对我们当地、全国和全球的影响，我们的工作是迫切需要的 社区及其对数百万已经或将在未来发展的人的潜在影响 通过阐明可能导致COVID19感染的机制、分子靶点和潜在的药物 直接用于开发新的抗病毒疗法和疗法。

Project summary In late 2019, COVID-19, a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) emerged in Wuhan, China and has rapidly impacted almost all countries around the world. Officially declared a global pandemic by the WHO, COVID-19 is a worldwide emergency and by million United with directly , current in vitro model platforms are so distinct from human infection that they may not capture key components of viral infection or virus-host interactions. May 29, 2020, over 5.8 COVID-19 cases were reported with over 360,000 deaths globally. Although originating in China the States has emerged as an epicenter of this pandemic with over 1.75 million COVID-19 cases reported over 103,000 deaths. Unfortunately there is no vaccine that can prevent SARS-CoV-2 infection or robust activing antivirals that can mitigate infection or alter disease progression. Moreover Given this local, national, and global emergency our near-term goal is on the development of novel and robust experimental cell culture models, virological tools, and to identify novel therapeutics for SARS-CoV-2 treatment. Our long-term goal is to elucidate the complex interactions and mechanisms underlying SARS-CoV-2 infection and host response. Given that our institution has been at the center of the COVID-19 pandemic here in the U.S. we have generated a wide database of clinical data that has revealed that a high prevalence of initial COVID- 19 presentations are with GI manifestations with over one-half of patients noted to have biochemical evidence of liver injury at presentation. The impact of SARS-CoV-2 infection on hepatocellular and cholangiocyte function remains unclear. To address these knowledge gaps we have generated several novel technologies and have assembled a robust team with complimentary expertise in stem cell biology, tissue engineering and virology, chemical screening and stem cell biology, and in virology/BSL3 expertise. We aim to identify drug candidates that impact SARS-CoV-2 viral infection while we evaluate host-virus interactions. Our work is urgently needed given the impacts SARS-CoV-2 has had on our local, national, and global communities and its potential impact on millions of people who already, or will in the future will develop COVID19 infection by shedding light on mechanisms, molecular targets, and potential drugs that could lead directly to the development of new antiviral treatments and therapies.